Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. (ALGS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ALGS · as of Sep 30, 2025
Ownership Breakdown
33
Institutional Holders
▼ 4 vs Q2
$25.99M
Total Inst. Value
▲ $6.48M vs Q2
6.19M
Shares Outstanding
freeFloat 77.71%
2.65M
13F Shares Held
▼ 54,565 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ALGS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
WOODLINE PARTNERS LP biological products, (no diagnostic substances) | 468.2K | 4.52% | 4.52% | $4.59B | Nov 14, 2025 | ▼ 50.1K |
DEEP TRACK CAPITAL, LP biological products, (no diagnostic substances) | 444.1K | 4.29% | 4.29% | $4.35B | Nov 14, 2025 | — held |
ALYESKA INVESTMENT GROUP, L.P. biological products, (no diagnostic substances) | 412.0K | 3.98% | 3.98% | $4.04B | Nov 17, 2025 | — held |
SIO CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 335.9K | 3.25% | 3.25% | $3.29B | Nov 13, 2025 | — held |
READYSTATE ASSET MANAGEMENT LP biological products, (no diagnostic substances) | 203.1K | 1.96% | 1.96% | $1.99B | Nov 7, 2025 | ▲ 66.3K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 171.7K | 1.66% | 1.66% | $1.68B | Nov 7, 2025 | ▲ 31.9K |
ADAGE CAPITAL PARTNERS GP, L.L.C. biological products, (no diagnostic substances) | 140.0K | 1.35% | 1.35% | $1.37B | Nov 14, 2025 | — held |
BAKER BROS. ADVISORS LP biological products, (no diagnostic substances) | 83.1K | 80.24% | 80.24% | $813.94M | Nov 14, 2025 | — held |
HHLR ADVISORS, LTD. biological products, (no diagnostic substances) | 76.2K | 73.66% | 73.66% | $747.22M | Nov 14, 2025 | — held |
LPL FINANCIAL LLC biological products, (no diagnostic substances) | 55.1K | 53.25% | 53.25% | $540.18M | Nov 12, 2025 | ▲ 25.0K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
12
Increased
+209.9K shares4
New Positions
first time holders6
Decreased
−68.7K shares9
Sold Out
fully exitedNet shares change (top 50)
+141.2K
+209.9K / −68.7K
Net new holders
+1
4 new / 9 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ALGS insider trading · insider activity
Source: SEC Form 4
3
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Aneja Nikhil Principal Accounting Officer | Mar 9, 2026 | Award | 9,450 | $7.03 | $66.4K | 9.4K | Form 4 ↗ |
Calhoun Lesley Ann See Remarks | Mar 9, 2026 | Award | 37,485 | $7.03 | $263.5K | 37.5K | Form 4 ↗ |
BLATT LAWRENCE President and CEO | Mar 9, 2026 | Award | 105,840 | $7.03 | $744.1K | 105.8K | Form 4 ↗ |
BLATT LAWRENCE President and CEO | Jul 16, 2025 | Award | 179,800 | $8.68 | $1.56M | 179.8K | Form 4 ↗ |
Symons Julian A. See Remarks | Jul 16, 2025 | Award | 16,000 | $8.68 | $138.9K | 16.0K | Form 4 ↗ |
Calhoun Lesley Ann See Remarks | Jul 16, 2025 | Award | 40,185 | $8.68 | $348.8K | 40.2K | Form 4 ↗ |
Nuechterlein Carole director | Jun 25, 2025 | Award | 5,860 | $7.63 | $44.7K | 5.9K | Form 4 ↗ |
Scopa James Paul director | Jun 25, 2025 | Award | 5,860 | $7.63 | $44.7K | 5.9K | Form 4 ↗ |
Hirth Peter director | Jun 25, 2025 | Award | 5,860 | $7.63 | $44.7K | 5.9K | Form 4 ↗ |
Preston Heather director | Jun 25, 2025 | Award | 5,860 | $7.63 | $44.7K | 5.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Aligos Therapeutics, Inc. (ALGS) is primarily owned by institutional investors, who hold approximately 42.9% of total shares outstanding. Company insiders own approximately 22.29%, while retail and public investors account for the remaining 34.86%.
The largest institutional shareholder of Aligos Therapeutics, Inc. is WOODLINE PARTNERS LP, holding approximately 468,199 shares — equal to 4.52% of outstanding shares — as of September 30, 2025.
A total of 33 institutional investors currently hold ALGS stock, with a combined institutional value of approximately $25,986,937 as of the most recent 13F filing period.
Frequently asked questions
ALGS ownershipAligos Therapeutics, Inc. (ALGS) is primarily owned by institutional investors, who hold approximately 42.9% of shares. The largest shareholder is WOODLINE PARTNERS LP with a 4.52% stake. Company insiders hold 22.29%. Data sourced from SEC Form 13F as of September 30, 2025.